Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deacon

Showing results (111-120 of 2,132) with videos related to

Pageof 214
Sort By:
Diabetes|August 28, 2004
Therapeutic strategies based on glucagon-like peptide 1Carolyn F Deacon
Regulatory Peptides|March 23, 2005
What do we know about the secretion and degradation of incretin hormones?Carolyn F Deacon
British Medical Journal|April 16, 1977
Beta-blockers and lipid metabolismS P Deacon
The New England Journal of Medicine|February 2, 1995
Clinical problem-solving: still hazy after all these yearsA C Deacon
Proceedings of the Royal Society of Medicine|October 5, 2010
Effect of Atenolol and other Beta Blockers on Insulin-induced HypoglycæmiaS P Deacon
Clinical Chemistry|July 1, 1990
Fecal porphyrin screeningA C Deacon
The Australian Journal of Physiotherapy|July 16, 2014
Sporting injuriesO W Deacon
Current Opinion in Investigational Drugs (London, England : 2000)|April 9, 2008
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetesCarolyn F Deacon
British Medical Journal|March 5, 1977
Metabolic effects of salbutamolS P Deacon
British Medical Journal|August 5, 1978
Money for old ropeS P Deacon
Pageof 214

Showing results (111-120 of 2,132) with videos related to

Sort By:
Pageof 214
Diabetes|August 28, 2004
Therapeutic strategies based on glucagon-like peptide 1Carolyn F Deacon
Regulatory Peptides|March 23, 2005
What do we know about the secretion and degradation of incretin hormones?Carolyn F Deacon
British Medical Journal|April 16, 1977
Beta-blockers and lipid metabolismS P Deacon
The New England Journal of Medicine|February 2, 1995
Clinical problem-solving: still hazy after all these yearsA C Deacon
Proceedings of the Royal Society of Medicine|October 5, 2010
Effect of Atenolol and other Beta Blockers on Insulin-induced HypoglycæmiaS P Deacon
Clinical Chemistry|July 1, 1990
Fecal porphyrin screeningA C Deacon
The Australian Journal of Physiotherapy|July 16, 2014
Sporting injuriesO W Deacon
Current Opinion in Investigational Drugs (London, England : 2000)|April 9, 2008
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetesCarolyn F Deacon
British Medical Journal|March 5, 1977
Metabolic effects of salbutamolS P Deacon
British Medical Journal|August 5, 1978
Money for old ropeS P Deacon
Pageof 214